Tradipitant Prevents Motion Sickness in Phase 3 Trial

Credit: Getty Images.
Tradipitant is a neurokinin-1 receptor antagonist.

Tradipitant was found to be superior to placebo in preventing vomiting associated with motion sickness, according to results from a phase 3 study.

The double-blind, placebo-controlled Motion Syros study ( Identifier: NCT04327661) included 365 individuals, with a prior history of motion sickness, who embarked on boat trips under varied sea conditions in the coastal waters of the US.

Participants were randomly assigned to receive tradipitant 170mg (n=120), tradipitant 85mg (n=123), or placebo (n=122). The primary endpoint of the study was reduction in the incidence of vomiting as measured by the Motion Sickness Severity Scale.

During each trip, sea conditions and participant-reported symptoms were recorded. Findings showed 18.3% and 19.5% of patients treated with tradipitant 170mg and 85mg, respectively, experienced vomiting compared with 44.3% of those who received placebo (P <.0001 for both). Based on these findings, Vanda expects to continue its motion sickness clinical program.

Tradipitant, a neurokinin-1 receptor antagonist, is also being developed for the treatment of gastroparesis.


Vanda Pharmaceuticals reports results from a phase III study of tradipitant in motion sickness. News release. Accessed May 25, 2023.